PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical ...
Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume 17.10.2023 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This week's life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results